Dodge & Cox
- SEC CIK
- 0000200217
- Latest filing
- Aug 13, 2026
NBIX holding history
Neurocrine Biosciences Inc in every 13F filed by Dodge & Cox, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
NBIX overviewAll 13F holders of NBIXFull Q2 2026 holdings
- Shares (Q2 2026)
- 5,584,707
- Value
- $941.2M
- % of portfolio
- 0.5%
- Quarters held
- 12
- Since Q3 2023
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 5,584,707 | $941.2M | 0.5% | +123,670+2.3% | Added | Holders |
| Q1 2026 | 5,461,037 | $719.4M | 0.4% | −47,005−0.9% | Reduced | Holders |
| Q4 2025 | 5,508,042 | $781.2M | 0.4% | −48,576−0.9% | Reduced | Holders |
| Q3 2025 | 5,556,618 | $780.0M | 0.4% | −10,196−0.2% | Reduced | Holders |
| Q2 2025 | 5,566,814 | $699.7M | 0.4% | +32,190+0.6% | Added | Holders |
| Q1 2025 | 5,534,624 | $612.1M | 0.3% | +2,518,199+83.5% | Added | Holders |
| Q4 2024 | 3,016,425 | $411.7M | 0.2% | +1,728,605+134.2% | Added | Holders |
| Q3 2024 | 1,287,820 | $148.4M | 0.1% | +7,000+0.5% | Added | Holders |
| Q2 2024 | 1,280,820 | $176.3M | 0.1% | +15,576+1.2% | Added | Holders |
| Q1 2024 | 1,265,244 | $174.5M | 0.1% | +5,500+0.4% | Added | Holders |
| Q4 2023 | 1,259,744 | $166.0M | 0.1% | +1,046,142+489.8% | Added | Holders |
| Q3 2023 | 213,602 | $24.0M | <0.1% | +213,602 | New | Holders |